<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04524390</url>
  </required_header>
  <id_info>
    <org_study_id>MRX-701</org_study_id>
    <nct_id>NCT04524390</nct_id>
  </id_info>
  <brief_title>Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai</brief_title>
  <acronym>EMBARK</acronym>
  <official_title>Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After Hepatoportoenterostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirum Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirum Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia&#xD;
      (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind randomized, placebo-controlled study in subjects with Biliary Atresia&#xD;
      with a primary endpoint at Week 26 followed by long-term open-label period during which all&#xD;
      subjects will receive maralixibat to Week 104.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in total serum bilirubin levels</measure>
    <time_frame>From baseline to Week 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in total serum bile acids</measure>
    <time_frame>From baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with total bilirubin levels &lt;2 mg/dL at Week 26</measure>
    <time_frame>At Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to liver transplantation or death</measure>
    <time_frame>From Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants undergoing liver transplantation or death</measure>
    <time_frame>From Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with liver-related clinical event, including liver transplantation, liver decompensation and death</measure>
    <time_frame>From Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in serum alanine aminotransferase (ALT)</measure>
    <time_frame>From Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in serum γ-glutamyltransferase (GGT)</measure>
    <time_frame>From Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in blood platelets</measure>
    <time_frame>From Baseline to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in serum albumin</measure>
    <time_frame>From Baseline to Week 26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Biliary Atresia</condition>
  <arm_group>
    <arm_group_label>Maralixibat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maralixibat oral solution administered twice daily, up to 600 microgram per kilogram, for 26 weeks and in the OLE for all patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral solution for 26 weeks. All placebo participants who complete Week 26 and continue in the open label extension (OLE) will receive maralixibat after Week 26.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maralixibat</intervention_name>
    <description>A small molecule inhibitor of the ileal bile acid transporter (IBAT)</description>
    <arm_group_label>Maralixibat</arm_group_label>
    <other_name>Formerly LUM001 and SHP625</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical to maralixibat except for the active drug substance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects with body weight ≥2500 g, who are ≥21 days old and &lt;90 days&#xD;
             old at the time of HPE (Kasai)&#xD;
&#xD;
          2. HPE or Kasai Procedure within 3 weeks prior to randomization&#xD;
&#xD;
          3. Clinical diagnosis of biliary atresia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with intractable chronic diarrhea at randomization&#xD;
&#xD;
          2. Subjects not tolerating enteral feeds at randomization&#xD;
&#xD;
          3. History of ileal resection&#xD;
&#xD;
          4. Diagnosis of biliary atresia splenic malformation syndrome or cystic biliary atresia&#xD;
&#xD;
          5. Evidence of another non-biliary atresia pathology involving the intrahepatic bile duct&#xD;
             (e.g., paucity, sclerosing cholangitis)&#xD;
&#xD;
          6. Evidence of liver failure (e.g. significant ascites)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Days</minimum_age>
    <maximum_age>111 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Mirum</last_name>
    <phone>+16506674085</phone>
    <email>clinicaltrials@mirumpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medinfo Mirum</last_name>
    <email>medinfo@mirumpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medstar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007-2113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Udeme Ekong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ryan Himes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer Vittorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kathleen Loomes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Squires, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mary Elizabeth Tessier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Baumann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik-Centrum Zdrowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Irena Jankowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vandana Jain, MBBCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biliary Atresia</keyword>
  <keyword>Kasai</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Congenital Abnormalities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Atresia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

